Johnson & Johnson (NYSE: JNJ) Stock Competitors & Peer Comparison
See JNJ's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for JNJ and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| JNJ | $272.09 | -0.48% | 645.3B | 24.96 | $10.73 | +1.95% |
| LLY | $1,264.44 | -1.24% | 1.2T | 39.56 | $31.49 | +0.53% |
| ABBV | $265.85 | -0.05% | 462.6B | 25.69 | $10.19 | +2.60% |
| MRK | $154.18 | +1.30% | 368.5B | 46.48 | $3.21 | +2.23% |
| NVS | $158.97 | -0.84% | 297B | 17.98 | $8.69 | +3.03% |
| AZN | $166.51 | +0.95% | 255.2B | 17.77 | $9.26 | +1.27% |
| AMGN | $439.85 | -0.57% | 234.1B | 19.39 | $22.37 | +2.26% |
| NVO | $46.87 | +0.84% | 205.1B | 11.49 | $4.02 | +2.51% |
| GILD | $147.33 | -0.18% | 178.1B | -367.79 | -$0.39 | +2.22% |
| PFE | $28.35 | +0.39% | 158.5B | 9.12 | $3.05 | +6.15% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
JNJ vs LLY Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, LLY has a market cap of 1.2T. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while LLY trades at $1,264.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas LLY's P/E ratio is 39.56. In terms of profitability, JNJ's ROE is +0.26%, compared to LLY's ROE of +0.93%. Regarding short-term risk, JNJ is less volatile compared to LLY. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check LLY's competition here
AbbVie Inc. (NYSE: ABBV)
JNJ vs ABBV Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, ABBV has a market cap of 462.6B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while ABBV trades at $265.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas ABBV's P/E ratio is 25.69. In terms of profitability, JNJ's ROE is +0.26%, compared to ABBV's ROE of -1.36%. Regarding short-term risk, JNJ is less volatile compared to ABBV. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
JNJ vs MRK Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, MRK has a market cap of 368.5B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while MRK trades at $154.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas MRK's P/E ratio is 46.48. In terms of profitability, JNJ's ROE is +0.26%, compared to MRK's ROE of +0.07%. Regarding short-term risk, JNJ is less volatile compared to MRK. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check MRK's competition here
Novartis AG (NYSE: NVS)
JNJ vs NVS Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, NVS has a market cap of 297B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while NVS trades at $158.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas NVS's P/E ratio is 17.98. In terms of profitability, JNJ's ROE is +0.26%, compared to NVS's ROE of +0.30%. Regarding short-term risk, JNJ is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
JNJ vs AZN Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, AZN has a market cap of 255.2B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while AZN trades at $166.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas AZN's P/E ratio is 17.77. In terms of profitability, JNJ's ROE is +0.26%, compared to AZN's ROE of +0.22%. Regarding short-term risk, JNJ is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
JNJ vs AMGN Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, AMGN has a market cap of 234.1B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while AMGN trades at $439.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas AMGN's P/E ratio is 19.39. In terms of profitability, JNJ's ROE is +0.26%, compared to AMGN's ROE of +0.89%. Regarding short-term risk, JNJ is less volatile compared to AMGN. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check AMGN's competition here
Novo Nordisk A/S (NYSE: NVO)
JNJ vs NVO Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, NVO has a market cap of 205.1B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while NVO trades at $46.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas NVO's P/E ratio is 11.49. In terms of profitability, JNJ's ROE is +0.26%, compared to NVO's ROE of +0.59%. Regarding short-term risk, JNJ is more volatile compared to NVO. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check NVO's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
JNJ vs GILD Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, GILD has a market cap of 178.1B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while GILD trades at $147.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas GILD's P/E ratio is -367.79. In terms of profitability, JNJ's ROE is +0.26%, compared to GILD's ROE of -0.16%. Regarding short-term risk, JNJ is less volatile compared to GILD. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
JNJ vs PFE Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, PFE has a market cap of 158.5B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while PFE trades at $28.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas PFE's P/E ratio is 9.12. In terms of profitability, JNJ's ROE is +0.26%, compared to PFE's ROE of +0.05%. Regarding short-term risk, JNJ is less volatile compared to PFE. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check PFE's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
JNJ vs BMY Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, BMY has a market cap of 133.8B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while BMY trades at $67.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas BMY's P/E ratio is 11.04. In terms of profitability, JNJ's ROE is +0.26%, compared to BMY's ROE of +0.47%. Regarding short-term risk, JNJ is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check BMY's competition here
Sanofi (NASDAQ: SNY)
JNJ vs SNY Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, SNY has a market cap of 108.4B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while SNY trades at $45.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas SNY's P/E ratio is 9.84. In terms of profitability, JNJ's ROE is +0.26%, compared to SNY's ROE of +0.06%. Regarding short-term risk, JNJ is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check SNY's competition here
GSK plc (NYSE: GSK)
JNJ vs GSK Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, GSK has a market cap of 104.1B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while GSK trades at $52.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas GSK's P/E ratio is 11.22. In terms of profitability, JNJ's ROE is +0.26%, compared to GSK's ROE of +0.24%. Regarding short-term risk, JNJ is less volatile compared to GSK. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
JNJ vs BIIB Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, BIIB has a market cap of 31.7B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while BIIB trades at $218.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas BIIB's P/E ratio is 13.53. In terms of profitability, JNJ's ROE is +0.26%, compared to BIIB's ROE of +0.05%. Regarding short-term risk, JNJ is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check BIIB's competition here
Zoetis Inc. (NYSE: ZTS)
JNJ vs ZTS Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, ZTS has a market cap of 31.5B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while ZTS trades at $77.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas ZTS's P/E ratio is 11.40. In terms of profitability, JNJ's ROE is +0.26%, compared to ZTS's ROE of +0.69%. Regarding short-term risk, JNJ is less volatile compared to ZTS. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check ZTS's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
JNJ vs HZNP Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas HZNP's P/E ratio is 61.86. In terms of profitability, JNJ's ROE is +0.26%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, JNJ is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
JNJ vs GRFS Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, GRFS has a market cap of 6.8B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while GRFS trades at $8.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas GRFS's P/E ratio is 9.18. In terms of profitability, JNJ's ROE is +0.26%, compared to GRFS's ROE of +0.08%. Regarding short-term risk, JNJ is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
JNJ vs OGN Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, OGN has a market cap of 3.6B. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while OGN trades at $13.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas OGN's P/E ratio is 4.10. In terms of profitability, JNJ's ROE is +0.26%, compared to OGN's ROE of +0.23%. Regarding short-term risk, JNJ is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check OGN's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
JNJ vs CELG-RI Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, CELG-RI has a market cap of 208.4M. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while CELG-RI trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, JNJ's ROE is +0.26%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, JNJ is more volatile compared to CELG-RI. This indicates higher risk in terms of short-term price fluctuations for JNJ.Check CELG-RI's competition here
Citius Oncology, Inc. (NASDAQ: CTOR)
JNJ vs CTOR Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, CTOR has a market cap of 70.6M. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while CTOR trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas CTOR's P/E ratio is -1.62. In terms of profitability, JNJ's ROE is +0.26%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, JNJ is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check CTOR's competition here
Scilex Holding Company (NASDAQ: SCLX)
JNJ vs SCLX Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, SCLX has a market cap of 49.2M. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while SCLX trades at $5.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas SCLX's P/E ratio is -0.15. In terms of profitability, JNJ's ROE is +0.26%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, JNJ is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
JNJ vs SCLXW Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, SCLXW has a market cap of 44.7M. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while SCLXW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas SCLXW's P/E ratio is N/A. In terms of profitability, JNJ's ROE is +0.26%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, JNJ is less volatile compared to SCLXW. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check SCLXW's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
JNJ vs MIRA Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, MIRA has a market cap of 29.8M. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while MIRA trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas MIRA's P/E ratio is -0.49. In terms of profitability, JNJ's ROE is +0.26%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, JNJ is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check MIRA's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
JNJ vs BDSIW Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, JNJ's ROE is +0.26%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, JNJ is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
JNJ vs CRXT Comparison August 2026
Johnson & Johnson (NYSE: JNJ) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, JNJ stands at 645.3B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, JNJ is priced at $272.09 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
JNJ currently has a P/E ratio of 24.96, whereas CRXT's P/E ratio is -0.02. In terms of profitability, JNJ's ROE is +0.26%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, JNJ is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for JNJ.Check CRXT's competition here